TD Cowen downgraded MacroGenics to Hold from Buy without a price target. The company’s efficacy was promising for the Phase 2 TAMARACK trial but safety deteriorated from the abstract “raises material questions,” the analyst tells investors in a research note. The firm says these include the timing and nature of the reported fatalities that were disclosed.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MGNX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
- Snap upgraded, Apple downgraded: Wall Street’s top analyst calls
- B. Riley starts MacroGenics at Buy on ‘de-risked’ lead asset
- MacroGenics initiated with a Buy at B. Riley
